On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

MSD is also bracing for a $200m hit due to tariffs as it accelerates US manufacturing and shifts its global supply strategy.

A steep fall in demand from China drove a 41% decline in MSD Q1 2025 sales of its human papillomavirus (HPV) vaccines Gardasil and Gardasil 9, marking a continued setback for the company’s ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

vaccine franchise, Gardasil/Gardasil 9 continued to underperform. While Merck’s (NYSE:MRK) cancer blockbuster Keytruda generated $7.2B in sales with ~4% YoY growth, GARDASIL/GARDASIL 9 sales ...

Merck said today its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a ...

Although the company lowered its full-year outlook for adjusted earnings per share to between $8.82 and $8.97 from between $8.88 and $9.03, that was only because the new guidance included an expected ...

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...